Preterm Birth and PROM Testing Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global preterm birth and PROM testing market size is expected to touch USD 2.21 Billion by 2030, from USD 1.66 Billion in 2021, growing with a significant CAGR of 3.2% from 2022 to 2030. 

The preterm birth and PROM testing report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global preterm birth and PROM testing in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global preterm birth and PROM testing market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global preterm birth and PROM testing during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1281

 Scope of the Preterm Birth and PROM Testing Market

Report Highlights	Details
Market Size	USD 2.21 Billion by 2030
Growth Rate	CAGR of 3.2% From 2022 to 2030
Base Year	2020
Historic Data	2017 to 2020
Forecast Period	2022 to 2030
Segments Covered	Test Type, End User
Regional Scope	North America, APAC, Europe, Latin America, MEAN, Rest of the World

This study covers a detailed segmentation of the global preterm birth and PROM testing market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global preterm birth and PROM testing market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• Abbott
• Qiagen N.V.
• Biosynex
• Hologic
• Cooper Surgical
• Sera Prognostics
• Medixbiochemica
• IQ Products
• NX Prenatal, Inc.
• Clinical Innovations, Inc.

Market Segmentation

 By Test Type

• Ultrasound
• Biochemical Markers
• Pelvic Exam
• Nitazine Test
• Uterine Monitoring
• Pooling
• Ferning Test
• Others

By End User

• Diagnostic Laboratories
• Hospitals
• Others

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Rest of the World

Research Methodology

The research methodology adopted by analysts for compiling the global preterm birth and PROM testing report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global preterm birth and PROM testing market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Preterm Birth and PROM Testing Market, By Test

7.1. Preterm Birth and PROM Testing Market, by Test Type, 2021-2030

7.1.1. Ultrasound

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Biochemical Markers

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Pelvic Exam

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Nitazine Test

7.1.4.1. Market Revenue and Forecast (2017-2030)

7.1.5. Uterine Monitoring

7.1.5.1. Market Revenue and Forecast (2017-2030)

7.1.6. Pooling

7.1.6.1. Market Revenue and Forecast (2017-2030)

7.1.7. Ferning Test

7.1.7.1. Market Revenue and Forecast (2017-2030)

7.1.8. Others

7.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Preterm Birth and PROM Testing Market, By End User

8.1. Preterm Birth and PROM Testing Market, by End User, 2021-2030

8.1.1. Diagnostic Laboratories

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Hospitals

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Preterm Birth and PROM Testing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.2. Market Revenue and Forecast, by End User (2017-2030)

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.2. Europe

9.2.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.3. APAC

9.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.4. MEA

9.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.4.2. Market Revenue and Forecast, by End User (2017-2030)

Chapter 10. Company Profiles

10.1. Abbott

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. Qiagen N.V.

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Biosynex

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. Hologic

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. Cooper Surgical

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Sera Prognostics

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. Medixbiochemica

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. IQ Products

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

10.9. NX Prenatal, Inc.

10.9.1. Company Overview

10.9.2. Product Offerings

10.9.3. Financial Performance

10.9.4. Recent Initiatives

10.10. Clinical Innovations, Inc.

10.10.1. Company Overview

10.10.2. Product Offerings

10.10.3. Financial Performance

10.10.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com